Screening for drug compounds with higher potency is of keen interest for many pharmaceutical drug development departments. Finding compounds which lead to the same response as a reference substance but at a lower dose can be the key to lower the risk of side-effects and to lower manufacturing costs. Parallel line analysis (PLA) is often applied in this context in order to prove parallelism of the underlying dose-response curves and subsequently estimate the relative potencies of substances compared to a reference substance. Here we describe how to apply PLA in BMG LABTECHs MARS data analysis software to inhibitor binding data to assess binding potencies of Prostaglandin D synthase inhibitors.
Using PLA, the (relative) binding potency of the hematopoietic prostaglandin D synthase inhibitor TFC 007 was estimated to be about 300-fold higher than that of the well-characterized HQL-79 imhibitor.